RT Journal Article
T1 Multiplexed monitoring of a novel autoantibody diagnostic signature of colorectal cancer using HaloTag technology-based electrochemical immunosensing platform
A1 Garranzo Asensio, María
A1 Guzmán Aránguez, Ana Isabel
A1 Povedano, Eloy
A1 Ruiz Valdepeñas Montiel, Víctor
A1 Povés Francés, Carmen
A1 Fernández Aceñero, María Jesús
A1 Montero Calle, Ana
A1 Solís Fernández, Guillermo
A1 Fernández Díez, Servando
A1 Camps, Jordi
A1 Arenas, Meritxell
A1 Rodríguez Tomás, Elisabeth
A1 Joven, Jorge
A1 Sánchez Martínez, Maricruz
A1 Rodrígez, Nuria
A1 Domínguez Muñóz, Gemma
A1 Yáñez Sedeño, Paloma
A1 Pingarrón Carrazón, José Manuel
A1 Campuzano Ruiz, Susana
A1 Barderas Manchado, Rodrigo
AB Background and Purpose: The humoral immune response in cancer patients can be used for early detection of the disease. Autoantibodies raised against tumor-associated antigens (TAAs) are promising clinical biomarkers for reliable cancer diagnosis, prognosis, and therapy monitoring. In this study, an electrochemical disposable multiplexed immunosensing platform able to integrate difficult- and easy-to-express colorectal cancer (CRC) TAAs is reported for the sensitive determination of eight CRC-specific autoantibodies.Methods: The electrochemical immunosensing approach involves the use of magnetic microcarriers (MBs) as solid supports modified with covalently immobilized HaloTag fusion proteins for the selective capture of specific autoantibodies. After magnetic capture of the modified MBs onto screen-printed carbon working electrodes, the amperometric responses measured using the hydroquinone (HQ)/H2O2 system were related to the levels of autoantibodies in plasma.Results: The biosensing platform was applied to the analysis of autoantibodies against 8 TAAs described for the first time in this work in plasma samples from healthy asymptomatic individuals (n=3), and patients with high-risk of developing CRC (n=3), and from patients already diagnosed with colorectal (n=3), lung (n=2) or breast (n=2) cancer. The developed bioplatform demonstrated an improved discrimination between CRC patients and controls (asymptomatic healthy individuals and breast and lung cancer patients) compared to an ELISA-like luminescence test.Conclusions: The proposed methodology uses a just-in-time produced protein in a simpler protocol, with low sample volume, and involves cost-effective instrumentation, which could be used in a high-throughput manner for reliable population screening to facilitate the detection of early CRC patients at affordable cost.
PB Ivyspring International Publisher
SN 1838-7640
YR 2020
FD 2020-02
LK https://hdl.handle.net/20.500.14352/6103
UL https://hdl.handle.net/20.500.14352/6103
LA eng
NO Ministerio de Economía y Competitividad (MINECO)
NO Instituto de Salud Carlos III/FEDER (European Regional Development Fund)
NO Ministerio de Ciencia e Innovación (MICCIN)
NO Comunidad de Madrid
NO Universidad Autónoma de Madrid
NO The Flanders Research Foundation (FWO)
NO Universidad Complutense de Madrid
DS Docta Complutense
RD 20 ago 2024